See more : Immuron Limited (IMC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Sigilon Therapeutics, Inc. (SGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigilon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Capita plc (CTAGY) Income Statement Analysis – Financial Results
- Iveco Group N.V. (IVCGF) Income Statement Analysis – Financial Results
- Property Solutions Acquisition Corp. (PSACU) Income Statement Analysis – Financial Results
- Novo Integrated Sciences, Inc. (NVOS) Income Statement Analysis – Financial Results
- Signify N.V. (PHPPY) Income Statement Analysis – Financial Results
Sigilon Therapeutics, Inc. (SGTX)
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 37.63M | 65.07M | 53.49M | 48.11M | 21.04M |
| General & Administrative | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Other Expenses | 1.45M | 55.00K | -89.00K | -6.00K | -81.00K |
| Operating Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Cost & Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Interest Income | 946.00K | 258.00K | 312.00K | 1.06M | 698.00K |
| Interest Expense | 2.29M | 1.99M | 1.20M | 650.00K | 289.00K |
| Depreciation & Amortization | 2.40M | 313.00K | 223.00K | 1.73M | 374.00K |
| EBITDA | -41.27M | -75.32M | -52.42M | -42.40M | -22.08M |
| EBITDA Ratio | -318.84% | -784.70% | -391.95% | -299.51% | -476.26% |
| Operating Income | -43.67M | -75.64M | -52.64M | -44.12M | -23.08M |
| Operating Income Ratio | -337.35% | -787.96% | -393.61% | -311.71% | -497.63% |
| Total Other Income/Expenses | 105.00K | -1.68M | -1.97M | 198.00K | 310.00K |
| Income Before Tax | -43.56M | -77.31M | -54.61M | -43.93M | -22.77M |
| Income Before Tax Ratio | -336.53% | -805.41% | -408.31% | -310.31% | -490.94% |
| Income Tax Expense | -105.00K | 925.00K | 259.00K | 644.00K | 599.00K |
| Net Income | -43.46M | -78.24M | -54.87M | -44.57M | -22.77M |
| Net Income Ratio | -335.72% | -815.04% | -410.25% | -314.86% | -490.94% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| Weighted Avg Shares Out | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
| Weighted Avg Shares Out (Dil) | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
Lilly Completes Acquisition of Sigilon Therapeutics
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
Eli Lilly to buy Sigilon Therapeutics on a massive premium
Eli Lilly to Acquire Sigilon Therapeutics
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
Lilly to Acquire Sigilon Therapeutics
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
10 Best-Performing Penny Stocks in the Health Care Sector
Source: https://incomestatements.info
Category: Stock Reports